Video Experimental Relacionado
Updated: Aug 5, 2026

08:49
Presynaptic Dopamine Dynamics in Striatal Brain Slices with Fast-scan Cyclic Voltammetry
Published on: January 12, 2012
La activación del receptor de dopamina D1 es requerida para la expresión postsináptica de los efectos del agonista D2
Resumen
Se requiere estimulación simultánea de los receptores de dopamina D1 y D2 para los efectos mediados por la dopamina en las neuronas de los ganglios basales y el comportamiento. Este hallazgo desafía la opinión de que los receptores D2 son los únicos que median estas respuestas.
Área de la Ciencia:
- La neurociencia es la neurociencia.
- Farmacología Farmacología.
- Ciencias del comportamiento Ciencias del comportamiento.
Sus antecedentes:
- Los receptores de dopamina, específicamente los subtipos D1 y D2, juegan un papel crucial en la regulación de la función de los ganglios basales y el comportamiento motor.
- Investigaciones anteriores sugirieron que los receptores de dopamina D2 podrían mediar de forma independiente cambios conductuales y neurofisiológicos inducidos por los agonistas de la dopamina.
Objetivo del estudio:
- Investigar las funciones sinérgicas de los receptores de dopamina D1 y D2 en la actividad neuronal de los ganglios basales y el comportamiento motor.
- Para determinar si los efectos mediados por el receptor D2 dependen de la estimulación concurrente del receptor D1 por la dopamina endógena.
Principales métodos:
- Registros electrofisiológicos de las neuronas de los ganglios basales en ratas.
- Evaluación de la actividad motora espontánea y comportamientos estereotipados.
- Manipulación farmacológica utilizando agonistas y antagonistas de los receptores de dopamina D1 y D2.
- El agotamiento de la dopamina endógena mediante el uso de alfa-metil-ro-tirosina.
Principales resultados:
- Los efectos neurofisiológicos y conductuales de los agonistas selectivos de D2 se atenuaron significativamente en ratas con dopamina endógena agotada.
- Los agonistas no selectivos de la dopamina o las combinaciones de agonistas D1 y D2 produjeron efectos robustos independientemente de los niveles endógenos de dopamina.
- Estos hallazgos indican que la eficacia del agonista del receptor D2 depende de la dopamina endógena que actúa en los receptores D1.
Conclusiones:
- Los resultados desafían la noción de que los receptores de dopamina D2 median por sí solos los cambios inducidos por la dopamina en la producción y el comportamiento de los ganglios basales.
- La estimulación simultánea de los receptores de dopamina D1 y D2 es necesaria para estos efectos.
- La interacción sinérgica entre los receptores de dopamina D1 y D2 es crítica para regular la función de los ganglios basales y el control motor.
Videos de Conceptos Relacionados
Drug-Receptor Interactions
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Dose-Response Relationship: Overview
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
The Two-State Receptor Model
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
The binding affinity of a drug determines its interaction with one...
Adrenergic Neurons: Neurotransmission
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...

